Teleflex Guides FY Continuing-Ops EPS to $2.84-$3.09
TFX sits 41% above its 52-week low of $100.18.
Summary
Teleflex put full-year continuing-operations EPS at $2.84 to $3.09, its first formal guide for the post-divestiture business, and separately sees full-year adjusted EPS of $7.50 to $7.75. The company reported third-quarter EPS of $22.28, adjusted EPS of $2.63 and net income of $927.4M. The range covers the slimmed-down company left after the $1.5B OEM sale closed in August, which also funded a $250M accelerated share repurchase and an $800M debt paydown. Continuing-ops framing matters because reported results still carry the divested unit and impairment noise from the $1.3B write-down booked earlier this year. The spread between the low and high end is wide, so the midpoint and the assumptions behind it will drive how the print is read. Q2 revenue rose 29% to $570.3M and management raised guidance then; this guide is the first full-year number for the new shape of the company.
At the time of this announcement, TFX was trading at $141.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $100.18 to $150.04. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.